Navigation Links
Unibioscreen and Drais Pharmaceuticals Partner to Develop and Commercialize UNBS 5162 for Treatment of Cancer
Date:9/15/2008

de discovered, patented & developed by Unibioscreen. In preclinical studies, UNBS 5162 has shown antitumor activity in several cancer models and is currently in a Phase I trial.

UNBS 5162 is anti-angiogenic in vivo, and has been shown to decrease CXCL chemokine expression in experimental prostate cancers. UNBS 5162 is a pan- antagonist of CXCL chemokines when administered in vitro chronically at 1 M, which is a drug concentration compatible with the doses used in vivo. The mode of action, as assessed by a National Cancer Institute comparative screen, appears to be unique.

In an orthotopic model of human refractory prostate cancer, UNBS 5162 has been demonstrated to function synergistically with the anti-tumor effects of taxol. The drug also increases the therapeutic benefits of radiotherapy.

The Phase I trial is currently being conducted under the supervision of Daniel Von Hoff, M.D. at TGen Clinical Research Services at The Virginia G. Piper Cancer Center at Scottsdale Healthcare, Mayo Clinic Scottsdale and the University of Arizona Cancer Center Tucson.

About Unibioscreen S.A.

Unibioscreen is a specialist oncology drug discovery and development company, working on novel, first-in-class compounds, with two blockbuster- potential drugs candidates starting clinical development.

Unibioscreen's core business is the identification and development of new chemical entities for the targeted treatment of cancer and its metastases. The company's focus is on cytotoxic/cytostatic chemotherapeutics that kill apoptosis-resistant and multidrug resistant cancer cells, and anti-migratory drug candidates that fight metastases. Most of Unibioscreen's drug candidates are derived from molecules observed in natural plants or marine invertebrates. Unibioscreen will continue to develop novel compounds in the clinic.

More information is available on http://www.unibioscreen.com

Ab
'/>"/>

SOURCE Drais Pharmaceuticals, Inc. and Unibioscreen S.A.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Vanda Pharmaceuticals Provides Update on Iloperidone
2. Cerimon Pharmaceuticals Announces Positive Results from a Phase II Clinical Study of Its Diclofenac Sodium Patch for Acute Pain
3. Jazz Pharmaceuticals, Inc. Announces Final Patient Has Completed Phase III Clinical Trial of Sodium Oxybate to Treat Fibromyalgia
4. Addrenex Pharmaceuticals Announces Positive Phase III Clinical Results for Clonicel to Treat ADHD
5. Celator Pharmaceuticals Receives Orphan Drug Designation for Anticancer Agent CPX-351
6. Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients
7. Aegerion Pharmaceuticals, Inc. adds Peter Garrambone to Board of Directors, Secures Additional Capital for Clinical Trials
8. Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD)
9. Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies
10. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
11. Indevus Pharmaceuticals Announces Completion of Enrollment in Phase III Trial of PRO 2000
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)...  Boston Scientific Corporation (NYSE: BSX ) is ... long-term growth strategies at a meeting with the investment ... . President and Chief Executive Officer Mike Mahoney ... to bring forward meaningful innovation to transform patient care, ... value. "We are focused on addressing ...
(Date:5/1/2015)... 2015 Cambrex Corporation (NYSE: CBM ) reports ... Highlights , Sales increased 18% compared ... foreign currency impact, driven by Innovator products and Controlled Substances. ... in the first quarter of 2014. , GAAP Diluted ... first quarter last year and Adjusted Diluted EPS was $0.29 ...
(Date:4/30/2015)... -- Omnicell, Inc. (NASDAQ: OMCL ), a leading provider ... today announced results for its first quarter ended March ... first quarter of 2015 was $116.2 million, up $14.5 ... and down $5.3 million or 4.4% from the fourth ... income as reported in accordance with U.S. generally accepted ...
Breaking Medicine Technology:Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 2Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 3Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 4Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 5Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 6Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 7Cambrex Reports First Quarter 2015 Financial Results 2Cambrex Reports First Quarter 2015 Financial Results 3Cambrex Reports First Quarter 2015 Financial Results 4Cambrex Reports First Quarter 2015 Financial Results 5Cambrex Reports First Quarter 2015 Financial Results 6Cambrex Reports First Quarter 2015 Financial Results 7Cambrex Reports First Quarter 2015 Financial Results 8Cambrex Reports First Quarter 2015 Financial Results 9Cambrex Reports First Quarter 2015 Financial Results 10Cambrex Reports First Quarter 2015 Financial Results 11Omnicell Announces First Quarter 2015 Results 2Omnicell Announces First Quarter 2015 Results 3Omnicell Announces First Quarter 2015 Results 4Omnicell Announces First Quarter 2015 Results 5Omnicell Announces First Quarter 2015 Results 6Omnicell Announces First Quarter 2015 Results 7Omnicell Announces First Quarter 2015 Results 8Omnicell Announces First Quarter 2015 Results 9Omnicell Announces First Quarter 2015 Results 10Omnicell Announces First Quarter 2015 Results 11Omnicell Announces First Quarter 2015 Results 12Omnicell Announces First Quarter 2015 Results 13Omnicell Announces First Quarter 2015 Results 14Omnicell Announces First Quarter 2015 Results 15Omnicell Announces First Quarter 2015 Results 16Omnicell Announces First Quarter 2015 Results 17Omnicell Announces First Quarter 2015 Results 18Omnicell Announces First Quarter 2015 Results 19Omnicell Announces First Quarter 2015 Results 20
... Dec. 20, 2011  Advocates working with the disability and ... Senators and House members to help stop a Medicare ... wheelchairs prescribed by their physicians. Seven ... Medicare and Medicaid Services (CMS) for a prepayment review ...
... OSAKA, Japan, Dec. 20, 2011 Takeda Pharmaceutical ... Pharmaceuticals North America, Inc., announced today that the ... (azilsartan medoxomil and chlorthalidone) for the treatment of ... is the only fixed-dose therapy in the U.S. ...
Cached Medicine Technology:Michigan Seniors and Disabled Population Face Restricted Access to Power Wheelchairs Unless Congress Stops New Medicare Program 2Michigan Seniors and Disabled Population Face Restricted Access to Power Wheelchairs Unless Congress Stops New Medicare Program 3Michigan Seniors and Disabled Population Face Restricted Access to Power Wheelchairs Unless Congress Stops New Medicare Program 4FDA Approves EDARBYCLOR (azilsartan medoxomil and chlorthalidone) for the Treatment of Hypertension 2FDA Approves EDARBYCLOR (azilsartan medoxomil and chlorthalidone) for the Treatment of Hypertension 3FDA Approves EDARBYCLOR (azilsartan medoxomil and chlorthalidone) for the Treatment of Hypertension 4FDA Approves EDARBYCLOR (azilsartan medoxomil and chlorthalidone) for the Treatment of Hypertension 5FDA Approves EDARBYCLOR (azilsartan medoxomil and chlorthalidone) for the Treatment of Hypertension 6FDA Approves EDARBYCLOR (azilsartan medoxomil and chlorthalidone) for the Treatment of Hypertension 7
(Date:5/2/2015)... ProText Kinetic 2 is a set of typography ... X. ProText Kinetic 2 features 40 animation presets ... X . Easily create interactive text videos without having ... Kinetic 2. , Using ProText Kinetic is as easy as ... presets in the FCPX timeline. Playback the default animation ...
(Date:5/2/2015)... 2015 Kare Visits LLC. launched in Chicago ... caregivers. Kare Visits offers relief for caregivers by visiting ... According to the Caregiver Action Network, eight in ... 20 hours a week caring for an elderly or disabled ... hire a nurse, a caregiver is now empowered to schedule ...
(Date:5/1/2015)... May 02, 2015 The Venetian on ... http://www.thevenetiangracebay.com , and it is elegant and sophisticated, ... white and attractive turquoise hues of Grace Bay Beach. ... seven percent of leisure travelers used their smartphones throughout ... were used in the planning and researching and continued ...
(Date:5/1/2015)... Costa Mesa, CA (PRWEB) May 01, 2015 ... sponsor at the Cerner Southeast Regional User Group (RUG) ... 2015. The Cerner Southeast Regional User Group Conference provides ... access to vendors who support all aspects of electronic ... innovative use of Cerner software applications. , In addition ...
(Date:5/1/2015)... (PRWEB) May 01, 2015 The Quail Creek ... American Cancer Society. Since 2001, the Quail Creek Relay team ... team host events throughout the year, including their biggest event, ... Golf Ball Drop. , Quail Creek Relay for Life ... battling cancer. Kate Kerwin, fitness director, states, “I was hooked ...
Breaking Medicine News(10 mins):Health News:Pixel Film Studios Announced the Release of Protext Kinetic 2 for FPCX. 2Health News:Chicagoan Seeks to Transform Industry by Launching an Innovative Elderly Care Solution 2Health News:Turks and Caicos Resort, The Venetian on Grace Bay, Launches New Web Presence 2Health News:TROY Healthcare to Exhibit at the Cerner Southeast Regional User Group Conference 2Health News:TROY Healthcare to Exhibit at the Cerner Southeast Regional User Group Conference 3Health News:Quail Creek Country Club’s Relay for Life Team Raised Over $89,000 for American Cancer Society 2
... Federation of Clinical Immunology Services meeting in San Diego ... the disabling inflammatory condition. ,Dr. Gregersen ... in his laboratory at the Robert S. Boas Center ... for Medical Research in Manhasset, NY and more than ...
... then the "medical condition" on whose basis Paris Hilton was ... inside a day later, was not depression, but a sexually ... World paper, the heiress has contracted an STI, and it ... the Los Angeles' Century Regional Detention Center decided to remove ...
... researchers at San Francisco VA Medical Center (SFVAMC) has found ... can predict people who may develop dementia within six years. ... furnishes 87 per cent accurate results, is a 14-point index ... ,Lead study author Dr. Deborah E. Barnes, a mental ...
... scans and tests of reading skills when taken together are ... ,The study was conducted by a team of ... School of Medicine. , ,As part of the ... 12, who were identified as struggling readers, ran for a ...
... A new mechanistic description of how tumor cells migrate ... tumor metastasis has been developed by a swiss-based ... for developing anti-metastasis therapies. ,Scientists know that ... dont understand the details of how this deadly migration ...
... estimated 11,000 Filipino nurses re-sat their examinations Monday after ... their results, an official said Monday . Lawyers hired ... Schools (CGFNS) acted as observers at examination centres in ... Arturo Brion said the graduates were re-taking the examinations ...
Cached Medicine News:Health News:New Developments in Rheumatoid Arthritis 2Health News:New Developments in Rheumatoid Arthritis 3Health News:Paris' 'medical Condition' is a Sexually Transmitted Infection 2Health News:Simple Test to Predict People Who may Develop Dementia Within Six Years 2Health News:Combination of Brain Scans, Reading Skill Tests can Predict Kids Reading Problems 2Health News:Developing Antimetastasis Therapy- An Early Stage of Tumor Control. 2Health News:Philippine Nurses Re-sit Scandal-tainted Exams 2
... Finnpipette Focus multichannel pipettes ... of reagents into microplates, ... 0.1-10 l volumes. The ... Finnpipette Focus multichannels, combined ...
... Research pro Electronic Pipette is ideal for ... Its easy-to-follow display, ergonomically-placed operating buttons, and ... reverse pipetting and diluting make this a ... functions of a manual pipette without any ...
The Biopette E has a comfortable, ergonomic design. Fully motorized piston drive. Virtually eliminates pipetting forces. User-friendly operator interface. Simple, precise volume setting. Rechargelabl...
... best value in high performance electronic pipetting!, ... design reduce hand fatigue and strain , ... ejector , Color coding for easy volume ... greater performance use Hamilton AdvanTip Low Retention ...
Medicine Products: